stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) Current ratio
BioMarin Pharmaceutical Inc.'s current ratio at the end of the quarter to 30 September 2026 was 2.4×, down 2.8× from fiscal 2025 (5.2×). Over the past ten years it has ranged from 2.1× (fiscal 2019) to 5.3× (fiscal 2024); the current reading is higher than 91% of that period. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.2× | (2.19%) |
| FY2024 | 5.3× | 112.04% |
| FY2023 | 2.5× | (46.25%) |
| FY2022 | 4.7× | 12.27% |
| FY2021 | 4.2× | (12.48%) |
| FY2020 | 4.8× | 128.32% |
| FY2019 | 2.1× | (47.00%) |
| FY2018 | 3.9× | 45.38% |
| FY2017 | 2.7× | (16.48%) |
| FY2016 | 3.2× | 32.31% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.4× | 2.35% |
| Jun 2026 | 2.4× | (58.89%) |
| Mar 2026 | 5.8× | 11.47% |
| Dec 2025 | 5.2× | 7.89% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | 11.1× |
| SMMT Summit Therapeutics PLC compare | 7.0× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| PCVX Vaxcyte, Inc. compare | 5.7× |
| IBRX ImmunityBio, Inc. compare | 5.7× |
| TECH Bio-Techne Corp compare | 4.5× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| TWST Twist Bioscience Corporation compare | 2.7× |
| BMRN BioMarin Pharmaceutical Inc. | 2.4× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement